Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety and interaction concepts are supported by the provided label excerpts (e.g., rhabdomyolysis/myopathy, liver enzyme abnormalities, liver function test timing, and drug interaction with strong CYP3A4 inhibitors/fibric acid derivatives/niacin/cyclosporine). However, multiple claims overreach beyond the supplied label details (e.g., tying liver enzyme elevations specifically to dose increases/other liver-affecting meds; characterizing dosage changes causing nausea/vomiting/diarrhea and headaches as side effects of dosage increases). Several indication-related claims (LDL/HDL/high triglycerides) are partially supported but not fully grounded in the excerpted label wording.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Label Mechanism of Action: LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase.
Statins work by reducing the production of cholesterol in the liver.
Label Mechanism of Action: inhibition of HMG-CoA reductase (rate-limiting enzyme).
Lipitor is used to treat high levels of LDL cholesterol ("bad" cholesterol).
Label 1.2 Hypeerlipidemia: reduces elevated total-C, LDL-C, apo B, and TG; and reduces total-C and LDL-C.
Lipitor is used for high triglycerides.
Label 1.2 Hypeerlipidemia: adjunct to diet to reduce treatment of patients with elevated serum TG levels (Fredrickson Type IV).
Lipitor is used to low levels of HDL cholesterol ("good" cholesterol).
Label 1.2: reduces elevated ... and to increase HDL-C.
Muscle pain and weakness are side effects of Lipitor dosage increases.
Label 5.1: myopathy defined as muscle aches or muscle weakness with increases in CPK.
Lipitor can cause an imbalance of certain enzymes in the muscles, leading to muscle damage.
Label 5.1: myopathy with increases in creatine phosphokinase (CPK) values.
Lipitor can cause liver enzyme elevations.
Label 5.2: statins associated with biochemical abnormalities of liver function; transaminase elevations.
Liver enzyme elevations can be a sign of liver damage.
Label 5.2: persistent elevations in transaminases; active liver disease/ unexplainable elevations are contraindications.
Rhabdomyolysis is a rare side effect of Lipitor.
Label 5.1: Rare cases of rhabdomyolysis with acute renal failure... have been reported.
Rhabdomyolysis from Lipitor can cause muscle damage.
Label 5.1: rhabdomyolysis and myopathy discussed; myopathy includes muscle aches/weakness and elevated CPK.
Rhabdomyolysis from Lipitor can cause kidney failure.
Label 5.1: rhabdomyolysis with acute renal failure secondary to myoglobinuria.
Pancreatitis is a rare side effect of Lipitor.
Label 6.1/6.2 excerpts provided do not mention pancreatitis; this item is therefore not supported by the supplied excerpts (see unsupported).
Lipitor can cause liver damage.
Label 5.2 and 6.2: hepatic failure and liver enzyme abnormalities discussed; active liver disease contraindicated.
Monitoring liver enzymes regularly can help identify potential liver damage early.
Label 5.2: recommended that liver function tests be performed prior to and at 12 weeks following initiation and any elevation of dose, and periodically (e.g., semiannually).
Starting with a low dosage of Lipitor and gradually increasing it can help minimize the risk of side effects.
Label 2.1: starting dose individualized; dosage range and titration with lipid levels analyzed within 2-4 weeks and adjusted accordingly. (Risk-minimization phrasing is not explicitly stated.)
Lipitor can interact with certain medications and increase the risk of side effects.
Label 7: risk of myopathy increased with concurrent administration of fibric acid derivatives, niacin (lipid-modifying doses), cyclosporine, or strong CYP3A4 inhibitors.
Unsupported Statements
Liver enzyme elevations can be a sign of liver damage.
Label excerpt supports transaminase elevations and contraindication for unexplained persistent elevations, but does not explicitly state that elevations are a sign of liver damage.
Liver enzyme elevations from Lipitor are more likely to occur when the dosage is increased.
Label excerpt provides timing for performing tests after any elevation of dose, but does not state that elevations are more likely to occur with higher dose.
Liver enzyme elevations from Lipitor are more likely to occur when Lipitor is taken with other medications that can affect the liver.
The provided label interaction excerpt (Section 7) addresses increased myopathy risk with specific drugs, not liver enzyme elevations or increased likelihood from other liver-affecting medications.
Dosage changes of Lipitor can cause nausea and vomiting.
Provided label excerpt lists nausea (0.4%) and diarrhea among common adverse reactions, but does not attribute them specifically to dosage changes or titration.
Dosage changes of Lipitor can cause diarrhea.
Diarrhea is listed as an adverse reaction, but the excerpt does not link diarrhea specifically to dosage changes.
Headaches are a common side effect of Lipitor dosage increases.
The provided adverse reactions excerpt does not list headaches; no statement ties headaches to dosage increases.
Pancreatitis is a rare side effect of Lipitor.
Provided label excerpts do not mention pancreatitis.
Pancreatitis from Lipitor can cause inflammation of the pancreas.
Pancreatitis is not mentioned in the provided excerpts.
Lipitor-induced liver damage is particularly more likely when the dosage is increased.
Provided label excerpt mandates liver function testing after dose elevation, but does not state increased likelihood of liver damage with dose increases.
Lipitor-induced liver damage is particularly more likely when Lipitor is taken with other medications that can affect the liver.
Provided interaction excerpt relates to increased myopathy risk with specific drugs; it does not state increased likelihood of liver damage/liver enzyme abnormalities from concomitant liver-affecting medications.
Contradictions
Important Omissions
Boxed warning status was not evaluated because no specific boxed warning content was provided in the supplied excerpts, and the AI claims included no pregnancy/breastfeeding contraindication statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims extend beyond supplied label text by implying increased likelihood of liver enzyme elevations/liver damage with dose increases or with other liver-affecting medications, and by asserting pancreatitis/headaches as common/rare—neither supported by provided excerpts. These could mislead monitoring/expectation framing beyond what the provided label excerpts state.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several safety and adverse reaction statements are either not supported by the provided label excerpts or over-attribute causality to dosage increases/titration and unspecified concomitant medications; pancreatitis/headaches are not supported by the supplied excerpts.
Suggested Improvement
Restrict statements to what the provided label excerpts explicitly support (e.g., myopathy/rhabdomyolysis and liver transaminase abnormalities with recommended test timing; drug interaction list in Section 7). Remove or qualify claims that are not present in the supplied label text (pancreatitis, headaches) and avoid asserting increased likelihood of liver enzyme elevations specifically with dose increases or with other liver-affecting drugs unless supported in the provided excerpts.